Ameriprise’s Applied Therapeutics APLT Stock Holding History

Ameriprise’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,431	Closed	-$165K	–	4083
2024 Q3	$165K	Buy	+19,431	New	+$115K	﹤0.01%	3782

Other funds holding APLT

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Ameriprise's APLT Position: Q4 2024 in Review

Ameriprise sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 19,431 shares — an estimated $165K sold.

Ameriprise first reported a position in APLT in Q3 2024 and held it in 1 quarter. The position peaked at $165K in Q3 2024. 119 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

Ameriprise reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
Ameriprise sold 19,431 Applied Therapeutics shares in Q4 2024, an estimated $165K.
Ameriprise first reported a position in Applied Therapeutics in Q3 2024 and held it in 1 quarter.
Ameriprise's Applied Therapeutics position peaked at $165K in Q3 2024.
119 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on Ameriprise's 13F filing for Q4 2024, filed 14 Feb 2025.